Kazia Therapeutics Limited (NASDAQ: KZIA)
$0.56
-0.3330 ( -37.20% ) 15.0M
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Market Data
Open
$0.56
Previous close
$0.90
Volume
15.0M
Market cap
$16.62M
Day range
$0.54 - $0.88
52 week range
$0.19 - $1.58
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Quarterly Reports | 3 | Jul 10, 2024 |
| 6-k | Quarterly Reports | 1 | Jun 24, 2024 |
| 6-k | Quarterly Reports | 1 | May 23, 2024 |
| 6-k | Quarterly Reports | 3 | May 17, 2024 |
| 6-k | Quarterly Reports | 3 | May 01, 2024 |
| 6-k | Quarterly Reports | 3 | Apr 19, 2024 |
| 6-k | Quarterly Reports | 97 | Mar 27, 2024 |
| 6-k | Quarterly Reports | 3 | Mar 26, 2024 |
| 6-k | Quarterly Reports | 2 | Feb 21, 2024 |
| 6-k | Quarterly Reports | 4 | Jan 18, 2024 |